Gao Dingcheng, Mittal Vivek
Department of Cardiothoracic Surgery, Lehman Brothers Lung Cancer Research Center, 1300 York Avenue, 525 East 68th street, New York, New York 10065, USA.
Trends Mol Med. 2009 Aug;15(8):333-43. doi: 10.1016/j.molmed.2009.06.006. Epub 2009 Aug 7.
Emerging evidence from murine models suggests that tumor-specific endocrine factors systemically stimulate the quiescent bone marrow (BM) compartment, resulting in the expansion, mobilization and recruitment of BM progenitor cells. Discrete subsets of tumor-instigated BM-derived progenitor cells support tumor progression and metastasis by regulating angiogenesis, inflammation and immune suppression. Notably, clinical studies have begun to reveal that increased BM recruitment in tumors is associated with poor prognosis. Thus, the BM-derived tumor microenvironment is an attractive therapeutic target, and drugs targeting the components of the microenvironment are currently in clinical trials. Here, we focus on recent advances and emerging concepts regarding the intriguing role of BM-derived cells in tumor growth, metastasis initiation and progression, and we discuss future directions in the context of novel diagnostic and therapeutic opportunities.
来自小鼠模型的新证据表明,肿瘤特异性内分泌因子可系统性刺激静止的骨髓(BM)区室,导致BM祖细胞的扩增、动员和募集。肿瘤引发的BM来源祖细胞的离散亚群通过调节血管生成、炎症和免疫抑制来支持肿瘤进展和转移。值得注意的是,临床研究已开始揭示肿瘤中BM募集增加与预后不良相关。因此,BM来源的肿瘤微环境是一个有吸引力的治疗靶点,目前针对微环境成分的药物正在进行临床试验。在这里,我们重点关注BM来源细胞在肿瘤生长、转移起始和进展中有趣作用的最新进展和新兴概念,并在新的诊断和治疗机会背景下讨论未来方向。